Boehringer Ingelheim's 2024 Sales Rise 6.1% Currency-Adjusted
By Patricia Weiss
INGELHEIM, Germany (Reuters) -Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.
Group sales reached 26.8 billion euros ($28.94 billion), the family-owned, unlisted drugmaker said in a statement.
Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly, made 8.4 billion euros in annual sales, a currency-adjusted increase of 14.6%.
Jardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca's Farxiga.
Annual sales of Boehringer's pulmonary fibrosis drug Ofev rose a currency-adjusted 8.9% to 3.8 billion euros, it added.
Boehringer is in a collaboration with Denmark's Zealand Pharma to develop a weight loss drug that the partners hope can be launched over the next few years, to compete with Lilly's recently launched obesity drug Mounjaro.
For 2025, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects.
($1 = 0.9261 euros)
(Writing by Ludwig BurgerEditing by Madeline Chambers)
